NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, Forecast & News

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $4.81 million. Eyepoint Pharmaceuticals had a negative return on equity of 250.32% and a negative net margin of 409.07%. View Eyepoint Pharmaceuticals' Earnings History.

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eyepoint Pharmaceuticals.

Eyepoint Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $19.3-20 million, compared to the consensus revenue estimate of $17.9 million.

4 brokers have issued 1 year price targets for Eyepoint Pharmaceuticals' shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Eyepoint Pharmaceuticals' stock price to reach $4.38 in the next year. This suggests a possible upside of 201.7% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.

News coverage about EYPT stock has trended somewhat negative recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyepoint Pharmaceuticals earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Eyepoint Pharmaceuticals.

Some companies that are related to Eyepoint Pharmaceuticals include Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Arrayit (ARYC), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX), Verastem (VSTM) and Amarin (AMRN).

Eyepoint Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (1.02%), Essex Investment Management Co. LLC (0.76%), Geode Capital Management LLC (0.76%), Integrated Advisors Network LLC (0.32%), Grimes & Company Inc. (0.09%) and UBS Group AG (0.08%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.

EYPT stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

EYPT stock was purchased by a variety of institutional investors in the last quarter, including Integrated Advisors Network LLC, State Street Corp, Grimes & Company Inc., UBS Group AG, Essex Investment Management Co. LLC, Barclays PLC, Geode Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, Ew Healthcare Partners, LP, George Elston, Jay S Duker, John B Landis and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYPT stock can currently be purchased for approximately $1.45.

Eyepoint Pharmaceuticals has a market capitalization of $156.77 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.View Additional Information About Eyepoint Pharmaceuticals.

The official website for Eyepoint Pharmaceuticals is http://eyepointpharma.com/.

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 833-393-7646 or via email at [email protected]